Emergent BioSolutions Loses Bid to Revive Narcan Spray Patents

A trial court was correct to rule that four patents for the Narcan opioid overdose treatment are invalid, a split U.S. appeals court ruled Thursday in a victory for Teva Pharmaceuticals.

• Opiant Pharmaceuticals and Emergent BioSolutions had argued that the judge in New Jersey erred in ruling that the patents were obvious variations of old ideas
• The companies had sued Teva to prevent it from selling a generic version of the drug
• The appeal was a “close case” but “we see no basis to disturb the district court’s ultimate legal conclusion of obviousness,” Circuit Judge Kara Stoll said in ...